Loading patent…
AssigneeBaker Norton Pharmaceuticals, Inc.
InventorsSamuel Broder, Kenneth L. Duchin, Sami Selim
Estimating the term…
A method of increasing the bioavailability upon oral administration of a pharmacologically active target agent, particularly an antitumor or antineoplastic agent which exhibits poor or inconsistent oral bioavailability (e.g., paclitaxel, docetaxel or etoposide), comprises the oral co-administration to a mammalian patient of the target agent and an oral bioavailability-enhancing agent (e.g., cyclosporin A, cyclosporin D, cyclosporin F or ketoconazole). The enhancing agent may be administered orally from 0.5-24 hrs. prior to the oral administration of one or more doses of the target agent, substantially simultaneously with the target agent or both prior to and substantially simultaneously with the target agent. A method of treating mammalian patients suffering from diseases responsive to target agents with poor oral bioavailability, as well as oral dosage forms containing such target agents, combination oral dosage forms containing bioavailability-enhancing agents and target agents and kits containing enhancing and target agent dosage forms and dosing information for the co-administration of the same are also disclosed.
A method of increasing the bioavailability upon oral administration of a taxane subject, comprising orally co-administering to the subject the taxane and an oral bioavailability enhancing agent, wherein the taxane reaches therapeutic activity levels in said subject.
A method of treating a subject afflicated with a condition responsive to a taxane comprising the oral co-administration to the subject of the taxane and an oral therapeutic acitivity levels in said subject.
The method of claim 27, wherein the taxane is docetaxel.
An oral dosage form comprising a taxane and a bioavailability enhancing agent, wherein the taxane achieves therapeutic activity levels when said oral dosage form is orally administered to a subject.
A kit comprising an oral dosage form containing an oral bioavailability enhancing agent and an oral dosage form containing a taxane, or a combination oral dosage form containing both the oral bioavailability enhancing agent and the taxane, wherein upon oral co-administration of the taxane and the oral bioavailability enhancing agent, therapeutic activity levels of the taxane are achieved.
A method of increasing the bioavailability upon oral administration of a taxane to a human subject, comprising orally co-administering to the human subject the taxane and an oral bioavailability enhancing agent, wherein the taxane reaches therapeutic activity levels in the human.
A method of increasing the bioavailability upon oral administration of a taxane to a subject, comprising orally co-administering to the subject the taxane and an oral bioavailability enhancing agent in separate oral dosage forms, wherein the taxane reaches therapeutic activity levels in the subject.
A method of increasing the bioavailability upon oral administration of a taxane to a human subject, comprising orally co-administering to the human subject the taxane and an oral bioavailability enhancing agent in separate oral dosage forms, wherein the taxane reaches therapeutic activity levels in the human subject.
The method of increasing the bioavailability upon oral administration of a taxane to a subject, comprising orally co-administering to the subject the taxane and an oral bioavailability enhancing agent, wherein said co-administering comprises orally administering the oral bioavailability enhancing agent prior to oral administration of the taxane, wherein the taxane reaches therapeutic acitivity levels in the subject.
A method of increasing the bioavailability upon oral administration of a taxane to a human subject, comprising orally co-administering to the human subject the taxane and an oral bioavailability enhancing agent, wherein said co-administering comprises orally administering the oral bioavailability enhancing agent prior to oral administration of the taxane, wherein the taxane reaches therapeutic activity levels in the human subject.
An oral dosage form comprising a taxane and a bioavailability enhancing agent, wherein the taxane achieves therapeutic activity levels when said oral dosage form is orally administered to a human subject.
Dependencies are inferred from the claim text.